Indoco Remedies Limited has informed the Exchange about Transcript
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indoco Remedies reported Q1 FY26 standalone net revenues of Rs. 383.8 crore (up 12.5% QoQ) and consolidated revenues of Rs. 429.1 crore, with margin recovery still in early stages—standalone EBITDA margin at 3.9% versus 13.1% a year ago. Management highlighted a 46%+ QoQ surge in the OTC business, a 26%+ rise in international solid oral exports, and a key win: European authorities approved Goa Plant-2 for sterile product supply, while the US FDA permitted 2 of 4 lines to restart. Total consolidated debt stood at Rs. 950 crore, down Rs. 21 crore QoQ, with a further Rs. 68 crore repayment planned over the remaining 9 months of FY26. CAPEX is being tightly controlled to about Rs. 50 crore incremental for the year, and R&D spend is expected to stay near 5–5.5% of sales with 4-5 product filings planned for FY26.
Shareholders can read this as a turn-in-progress story: regulatory headwinds are easing (US FDA partial clearance, EU GMP approval), debt is being chipped down, and management has committed to sequential improvement with a target to return to the historical 11–13% EBITDA band. However, near-term margins remain weak and management declined to give a specific margin or revenue recovery timeline, keeping the stock in a 'watch and wait' zone until US sterile supply and Goa Plant-2 remediation close out in Q3–Q4 FY26.